ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGRY vs AXGN // EV/EBITDA & P/E VALUATION

Surgery Partners Inc. (NASDAQ) VS. Axogen Inc. (NASDAQ) • 15-METRIC TALLY: SGRY 6 — AXGN 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGRY VS. AXGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGRY AXGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% -2.60% +12.50 SGRY /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 9.7x — — TIE /valuation <GO>
Free Cash Flow Yield 6.44% -0.10% +6.54 SGRY /fcf-yield <GO>
Operating Margin 45.80% -3.50% +49.30 SGRY /operating-margins <GO>
Net Profit Margin -9.20% -7.00% -2.20 AXGN /net-margins <GO>
Revenue Growth (YoY) 6.60% 20.20% -13.60 AXGN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.67 18.64 -17.97 AXGN /balance-sheet <GO>
Piotroski F-Score Quality 8/9 6/9 +2.00 SGRY /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 86.2 74.3 +11.90 SGRY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.99 1.10 -0.11 AXGN /macro-sensitivity <GO>
Forward P/E Multiple 22.0x 18.0x +4.00 AXGN /forward-pe <GO>
Enterprise Scale & Market Cap $3.04B $2.96B $74.2M SGRY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGRY REV AXGN REV SGRY GROSS % AXGN GROSS % SGRY FCF AXGN FCF
FY 2025 $0 $225.2M — 74.3% $195.6M -$2.9M
FY 2024 $0 $187.3M — 75.8% $209.7M $1.4M
FY 2023 $0 $159.0M — — $293.8M -$12.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGRY // BETA 0.99
AXGN // BETA 1.10